Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Adebrelimab in Combination With NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer

NCT06475326 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06475326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06475326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Adebrelimab in Combination With NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
June 5, 2024
Completion date
December 31, 2025
Enrollment
87 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer